Stablepharma Ltd
Industrial Biotech
- [email protected]
- Phone
- +441225424708
- Website
- https://stablepharma.com/contact
- Membership category
- Corporate
8, St James's Square, London, SW1Y 4JU, United Kingdom
Stablepharma Ltd at a glance
Pioneering a new era of fridge free vaccines and pharmaceuticals
StablevaX™ platform enables the reformulation of vaccines and pharmaceutical products into thermostable forms that remain safe and effective at temperatures of 40°C and above.
StablevaX™ technology underpins the development of a new generation
of fridge-free vaccines & pharmaceuticals.
Leading this portfolio is SPVX02 —the first-ever thermostable tetanus
and diphtheria vaccine to advance into clinical evaluation.
About Stablepharma Ltd
Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. Stablepharma has developed a stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world. StablevaX™ is designed to dramatically enhance the performance of existing and new vaccines. Stablepharma stands to revolutionise the vaccine industry, by helping shield vaccines from temperature-related deterioration and wastage. StablevaX™ has shown strong in-vitro and in-vivo data on stabilising range of vaccines including Tetadif (Td) and naked COVID mRNA. Stablepharma R&D team believe that the StablevaX™ technology could be applicable to over 60 vaccines.